Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 20 Nov 23 EFFECT Notice of effectiveness
- 9 Nov 23 POS AM Prospectus update (post-effective amendment)
- 25 Nov 22 424B3 Prospectus supplement
- 10 Nov 22 424B3 Prospectus supplement
- 11 Aug 22 424B3 Prospectus supplement
- 13 May 22 424B3 Prospectus supplement
- 29 Mar 22 EFFECT Notice of effectiveness
- 23 Mar 22 POS AM Prospectus update (post-effective amendment)
- 10 Jan 22 424B3 Prospectus supplement
- 27 Dec 21 EFFECT Notice of effectiveness
- 23 Dec 21 424B3 Prospectus supplement
-
21 Dec 21 S-1 IPO registration
EQRX similar filings
Filing view
External links
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated August 25, 2021, with respect to the consolidated financial statements of EQRx, Inc. included in the Registration Statement (Form S-1) and related Prospectus of EQRx, Inc. (formerly known as CM Life Sciences III, Inc.) for the registration of 220,307,414 shares of its common stock and 8,693,333 warrants to purchase shares of common stock.
/s/ Ernst & Young LLP
Boston, Massachusetts
December 20, 2021